Clinical Study of Decitabine and Paclitaxel Combination Therapy
Phase Ib clinical study of Decitabine and Paclitaxel combination therapy
Advanced Breast Cancer
DRUG: Decitabine|DRUG: Paclitaxel
Maximum Tolerant Dose (MTD) and Dose Limiting Toxicity (DLT), According to principle of Dose Limited Toxicity (DLT) assessment by National Cancer Institute Common Terminonlgy Criteria for Adverse Events (NCI-CTCAE, V4.0), DLT is evaluated above grade 3 as adverse event., for about 4 weeks
An open-labelled, parallel, multiple ascending dose, phase Ib clinical study of Decitabine and Paclitaxel combination therapy in treating patients with metastatic and locally advanced breast cancer